Experimental drug to treat liver cancer shows evidence of activity with manageable side effects
Exercise testing detects silent cardiovascular dangers common in pediatric cancer survivors
27 October 2022Preliminary data suggest that ROS1 inhibitor, NVL-520, is well-tolerated and active in non-small cell lung cancer
28 October 2022Experimental drug to treat liver cancer shows evidence of activity with manageable side effects
A new drug that inhibits an enzyme playing a crucial role in cell division and growth has shown signs of anti-cancer activity with manageable side effects in liver cancer patients who have been treated unsuccessfully previously with up to three lines of treatment.
